Research programme: riburamycins - sanofi-aventis

Drug Profile

Research programme: riburamycins - sanofi-aventis

Alternative Names: Fluorinated riburamycins research programme - sanofi-aventis; MraY inhibitors research programme - sanofi-aventis; Riburamycins research programme - sanofi-aventis; RU 75411

Latest Information Update: 17 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Class
  • Mechanism of Action Enzyme inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 17 Aug 2007 No development reported - Preclinical for Bacterial infections in France (unspecified route)
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
  • 22 Jan 2003 Preclinical trials in Bacterial infections in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top